AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-Mercaptopurine
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Study NCT03840304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga@work
Description: Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
Study NCT02962895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736
Study NCT02962895 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT02878525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic internal gastric banding
Description: Laparoscopic internal gastric banding
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Part of standard chemotherapy
Study NCT04056754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
Study NCT04056754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects administered 5mg prednisone twice daily in 28-day cycle.
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegaspargase
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Part of standard chemotherapy
Study NCT05025189 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beige Diet
Description: Low Fiber, low polyphenol Diet
Study NCT00749918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Description: Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
Study NCT03857243 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dual transcranial direct current stimulation
Description: Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
Study NCT03857243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual transcranial direct current stimulation
Description: Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
Study NCT00330564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
Study NCT02878525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy
Study NCT04040595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal fat biopsy
Description: A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
Study NCT01304212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
Study NCT01304212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine,morphine chloride,epinephrine,ketorolac
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
Study NCT01304212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
Study NCT01304212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine ,ketorolac
Description: ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
Study NCT02607917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mass Media plus clinic intervention.
Study NCT02607917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose
Study NCT00649623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan Medoxomil Tablets 40 mg
Description: 40mg, single dose fasting
Study NCT00649623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benicar® Tablets 40 mg
Description: 40mg, single dose fasting
Study NCT04056754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Subjects administered 5mg prednisone twice daily in 28-day cycle.
Study NCT01814605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infragluteal space group
Description: Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tioguanin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tioguanin
Description: Part of standard chemotherapy
Study NCT01814605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgluteal space group
Description: Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
Study NCT04269694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medihoney dressing
Description: Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy
Study NCT04269694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medihoney dressing
Description: Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Part of standard chemotherapy
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vindesine
Description: Part of standard chemotherapy
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
Study NCT03643276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (IT)
Description: For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
Description: For patients with CNS 3, on Days 1, 8, 15, 22, and 29
Study NCT02393547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All subjects receive Varenicline
Study NCT05197127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton-based gait training
Description: Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
Study NCT03339544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex premedication
Description: celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
Study NCT02393547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: All subjects receive Lorcaserin
Study NCT03018509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451
Description: Active drug tablets containing JTE-451
Study NCT03817320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
Study NCT03339544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is given as a tablet before initiation of endodontic treatment
Study NCT01375699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: As prescribed by treating provider.
Study NCT04296929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Physiotherapy
Description: Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
Study NCT03085342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver MRI
Description: Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
Study NCT02721290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block using Ultrasound and neurostimulator
Study NCT02721290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block using Ultrasound
Study NCT02721290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
Study NCT02721290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
Study NCT03648502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cognitive tests and hearing tests
Description: Several cognitive and hearing (peripheral and (central) auditory process) tests
Study NCT03648502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive tests and hearing tests
Description: Several cognitive and hearing (peripheral and (central) auditory process) tests
Study NCT03648502 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive tests and hearing tests
Description: Several cognitive and hearing (peripheral and (central) auditory process) tests
Study NCT02239029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
Study NCT02239029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The normal salin as the placebo intervention was injection in the other side of knee.
Study NCT04315298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
Study NCT01602783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C Acetate Imaging
Description: Single scan
Study NCT04315298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
Study NCT01933399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inextensible LSO (stiff back support)
Description: Cotton/nylon canvas back support with velcro fasteners.
Study NCT01933399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensible LSO, a back support that is flexible
Description: Back support is constructed from lycra and neoprene with velcro fasteners.
Study NCT01933399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
Study NCT03474627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-coated HA/TCP particles
Description: Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
Study NCT02635139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast skipping
Description: 18h fasting period in the morning
Study NCT03474627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLGA-coated HA/TCP particles
Description: Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
Study NCT01865136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical Post Abortion Care
Description: Women with incomplete abortion is diagnosed and treated with misoprostol
Study NCT03840681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmentation
Description: non invasive technique to increase bone width and eliminate need for second surgery
Study NCT03840681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Augmentation
Description: non invasive technique to increase bone width and eliminate need for second surgery
Study NCT03844061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
Study NCT03844061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
Study NCT03844061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Subcutaneous Injection
Description: Normal Saline
Study NCT03844061 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Normal Saline
Study NCT03844061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMF
Description: MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
Study NCT03844061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
Study NCT02048774 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Designation of Social Positioning
Study NCT02048774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designation of Social Positioning
Study NCT03721549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk GI.1 Virus
Description: Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
Study NCT04461145 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: command
Description: The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
Study NCT00820313 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dr. Dean Ornish Program for Reversing Heart Disease
Description: Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program.